Moderna Inc (MRNA) Stock

Valuation data is not available for this stock.

With a beta of 1.83, Moderna Inc is significantly more volatile than the market. For every 10% market move, this stock tends to move 18% in the same direction. Higher beta stocks offer greater potential returns but with increased risk. The price-to-book ratio of 1.00 indicates the stock trades below its accounting value, which could signal value or distress.

Moderna Inc achieves a profit margin of -94.30%, meaning it retains $-94.30 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of -639.00% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -27.50% and ROA at -14.80%, the company achieves moderate returns on invested capital.

Moderna Inc's revenue declined by 41.10% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. Earnings decreased by 85.10% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry averages for proper context.

Moderna Inc has a market capitalization of $9.37B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 389.08M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry, it competes with other firms in this sector.

Moderna Inc's book value per share is $24.16, while the current stock price is $23.51, resulting in a price-to-book (P/B) ratio of 0.97. Trading below book value can indicate the market perceives challenges ahead, or it might represent a value opportunity if the assets are quality and earnings can recover. Value investors often screen for P/B ratios below 1.0. As a common stock, this represents equity ownership with voting rights.

25 analysts cover MRNA with 20% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The bearish sentiment could create opportunity if analysts are wrong. The consensus target of $45.45 implies 93.3% upside, but targets are often adjusted to follow price moves rather than predict them.

Current analyst recommendations:1 Strong Buy, 4 Buy, 16 Hold, 1 Sell, 3 Strong Sell. The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

RSI data is not available for this stock.

MACD and moving average data are not available for this stock.